Health
Pulsesight Therapeutics Presents New Data On PST-611 Transferrin Vectorized Therapy For Geographic Atrophy At EVER Congress 2024
(MENAFN - GlobeNewsWire - Nasdaq) PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with ...
By: menafn
- Nov 06 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS